CARsgen Therapeutics has claimed the world’s first clinical win for a Claudin 18.2-targeting chimeric antigen receptor (CAR) T-cell therapy in the treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, paving the way for the submission of a new drug application in China in the first half of 2025.
CARsgen Claims First Clinical Win For CLDN 18.2 CAR-T In G/GEJ Adenocarcinoma
CARsgen's anti-Claudin 18.2 CAR-T therapy satricabtagene autoleucel has met its endpoint in a pivotal Phase II trial in later-stage gastric/gastroesophageal junction adenocarcinoma, paving the way for a China NDA filing.
